Charles River Laboratories’ virtual control group (VCG) database will be used in a toxicology study run by French biopharma ...

AbbVie has added another angle to its relationship with Nxera, with the Big Pharma paying $100 million upfront for a phase ...

Ultragenyx is laying off 20% of its workforce and axing drug development programs to cut its annual R&D budget to half of the ...

Fierce has reached out to Novartis to understand the reasons for ending the collaboration. (iStock / Getty Images Plus) Just 14 months after Novartis signed an $800 million biobucks neuroscience ...

AbbVie has scrapped a phase 2 solid tumor drug after deciding that the monoclonal antibody was unlikely to best the current ...

Originally, Rhythm licensed the melanocortin 4 receptor (MC4R) candidate, known at the time as LB54640, from LG for $80 ...

Pfizer has axed a phase 2 pulmonary arterial hypertension program on business grounds, dealing a setback to a long-running ...

Philips recorded a provision of 288 million euros ($322 million) for the proposed settlement in the third quarter, with payment “expected in the first quarter of 2027.” A separate investigation by U.S ...

The PASI 90 rate, which is in line with the phase 2 result, looks competitive. Cross-trial comparisons can be unreliable, ...

Tiziana Life Sciences’ intranasal drug has hit the dual endpoints of a phase 2a study in patients with a form of multiple sclerosis (MS), although the win was slightly marred by the higher dose ...

Teva has given up on a key trial of one of its original lineup of innovative medicines. | Teva has given up on a key trial of ...

The FDA has put a partial hold on Biosciences’ seizure study application over preclinical toxicity data and concerns about ...